晚期肾癌的外科管理:减瘤性肾切除术与淋巴结清扫的作用
本文综述了减瘤性肾切除术与淋巴结清扫在晚期肾癌中的治疗角色,梳理从免疫治疗到靶向治疗时代的证据。CARMENA试验显示中危和低危患者在舒尼替尼治疗下减瘤性肾切除术无获益,而 favorable-risk 亚组的1级证据尚待 TARIBO 试验。淋巴结清扫在 cT1-2N0M0 和 cM1 患者中提示无治疗获益,高危患者获益不确定,指南推荐较弱。
要点
- CARMENA试验显示中危和低危转移性肾癌患者在舒尼替尼治疗下减瘤性肾切除术无生存获益。
- favorable-risk亚组减瘤性肾切除术的1级证据尚待TARIBO试验结果。
- 淋巴结清扫在cT1-2N0M0和cM1患者中提示无治疗获益,高危患者获益不确定。
核心结论
- 减瘤性肾切除术在靶向治疗时代对中危和低危转移性肾癌患者无生存获益,favorable-risk亚组证据待定。
- 淋巴结清扫在cT1-2N0M0和cM1肾癌患者中提示无治疗获益,高危患者获益不确定,指南推荐较弱。
研究设计与样本
- 本文为综述,批判性评估减瘤性肾切除术和淋巴结清扫在晚期肾癌中潜在治疗作用的文献。
主要发现
- 回顾性数据支持靶向治疗时代减瘤性肾切除术的生存获益与初始免疫治疗时代(1992至2006年)相似。
- CARMENA随机试验的1级证据显示中危和低危患者在舒尼替尼治疗下减瘤性肾切除术无获益。
- SURTIME试验比较了靶向治疗前先行减瘤性肾切除术与初始靶向治疗后延迟减瘤性肾切除术。
- 淋巴结清扫在cT1-2N0M0和cM1疾病中强烈提示无治疗获益,在高危疾病(即局部晚期或cN1M0)中获益不确定。
临床怎么用
- 中危和低危转移性肾癌患者接受舒尼替尼治疗时,不应常规推荐减瘤性肾切除术。
- favorable-risk患者的减瘤性肾切除术决策需等待TARIBO试验结果。
- cT1-2N0M0和cM1肾癌患者不推荐常规淋巴结清扫,高危患者需个体化评估。
局限性
- favorable-risk亚组减瘤性肾切除术的1级证据尚待TARIBO试验。
- 淋巴结清扫在高危患者中的获益不确定,指南推荐较弱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the evolution of systemic therapy from the immunotherapy to targeted therapy eras, surgical management remains a mainstay of treatment of patients with locally advanced, lymph node-positive, and distant metastatic renal cell carcinoma. Balancing patient and disease characteristics with the potential morbidity of surgery has gained increasing attention to better define the role of cytoreductive nephrectomy and lymphadenectomy. In this review, we critically evaluate the literature for the potential therapeutic role of cytoreductive nephrectomy and lymphadenectomy in advanced kidney cancer, highlighting current evidence, limitations, and best-management practices. Although retrospective data supported a similar survival benefit for cytoreductive nephrectomy in the targeted therapy era as it did for the initial immunotherapy era (1992 to 2006), level 1 evidence from the randomized Clinical Trial to Assess the Importance of Nephrectomy (CARMENA) demonstrated no benefit for intermediate- and poor-risk patients in the setting of sunitinib therapy. Level 1 evidence among a favorable-risk subset is still awaited from the trial Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery (TARIBO). Another trial, Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME), has compared upfront cytoreductive nephrectomy prior to targeted therapy with the initial initiation of targeted therapy followed by deferred cytoreductive nephrectomy. Lymphadenectomy is yet another controversial but less well-defined management option for patients with kidney cancer. The role of lymphadenectomy has been studied in both the localized and advanced settings over the past few decades, with a strong suggestion of no therapeutic benefit for patients with cT1-2N0M0 and cM1 disease, and with uncertain benefit in patients with high-risk disease (ie, locally advanced or cN1M0), leading to weak statements among clinical guidelines.
引用
- Patel HD, Karam JA, Allaf ME, et al. Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy. J Clin Oncol. 2018. PMID: 30372387. doi:10.1200/JCO.2018.79.0246
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。